Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832192 · ClinicalTrials.gov registry record · Phase 2
Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study
A Phase 2 study of Delirium and Fall Injury, sponsored by Victor Wang.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 1
- Study location
NCT03832192: Completed Phase 2 study of Delirium and Fall Injury, sponsored by Victor Wang.
NCT03832192 is a Phase 2 study of Delirium and Fall Injury that has completed, run by Victor Wang. The registered enrollment target is 301 participants, below the 883-participant average among 62 other Delirium trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832192, a Phase 2 study of Delirium and Fall Injury, has completed, sponsored by Victor Wang.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 1
- Study location
Study Summary
Through NINR project 1R44NR017842-01 which preceded the present study, the investigators enhanced the care.coach avatar platform to incorporate a robust suite of evidence-based protocols based on the Hospital Elder Life Program (HELP), and to leverage an integration with hospital-based electronic medical record (EMR) systems. In the present study, the investigators seek to validate the efficacy of the new avatar platform, as measured by reduction in falls, delirium, and patient sitter utilization. Also, the investigators seek to gather patient and outcomes data at a scale sufficient to begin developing machine learning algorithms for intelligent, automatic assignment of protocols to maximize patient engagement and clinical efficacy, and for intelligent, automatic screening of delirium to assist care teams in positive identification of delirium. Therefore, the present study comprises a two-year randomized between-groups comparison across multiple hospitals to compare outcomes with the new generation of care.coach avatars as the intervention versus usual care only as the control. Each study group will be geographically distributed across participating research sites: initially MediSys Health Network's Jamaica Hospital Medical Center in New York, with additional hospitals to join the study over the course of two years.
Primary Outcome
For each patient without prevalent delirium (each patient who screens negative per the Confusion Assessment Method \[CAM\] upon study enrollment, which is assumed to be within 24 hours of admission to the hospital unit), Incident Delirium is indicated by any positive CAM screen during the patient's study enrollment period, with CAM screens being performed at least daily (the final CAM screen is assumed to be within 24 hours of discharge from the hospital unit). Incident Delirium is thus a binary
Conditions Studied
Interventions
- BEHAVIORAL care.coach Avatar (HELP-Protocolized)
Study Locations (1)
New York
- Jamaica Hospital Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2019-01-08 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 2 |
What the finished NCT03832192 record still lists
NCT03832192 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 883-participant average among 62 other Delirium trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Delirium appearing as the primary indexed condition, and to 1 intervention - of which care.coach Avatar (HELP-Protocolized) is the first listed.
NCT03832192 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03832192 about?
NCT03832192 is a clinical study titled "Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study". Through NINR project 1R44NR017842-01 which preceded the present study, the investigators enhanced the care.coach avatar platform to incorporate a robust suite of evidence-based protocols based on the Hospital Elder Life Program (HELP), and to leverage an integration with hospital-based electronic me...
What is the current status of trial NCT03832192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2019-01-08. Estimated completion is 2021-01-07.
What conditions does trial NCT03832192 study?
This clinical trial studies the following conditions: Delirium, Fall Injury.
What interventions are being tested in trial NCT03832192?
The interventions under investigation include: care.coach Avatar (HELP-Protocolized) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03832192?
This trial is sponsored by Victor Wang, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03832192 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03832192's enrollment target sits among peer trials
301 25th of 62 higher than 38 of 62 other Delirium trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
RECRUITING · Phase 2
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
-
Investigation of Sleep in the Intensive Care Unit
COMPLETED · Phase 2
-
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI